FDA Enhances Speed and Transparency of Actions Taken Against Misconduct
FDA Enhances Speed and Transparency of Actions Taken Against Misconduct in Drug and Device Development
The Food and Drug Administration today announced it has stepped up its efforts to prevent non-compliant investigators and others from participating in new product development. FDA s procedures for debarment and disqualification have been enhanced to better protect participants in clinical studies and for ensuring the safety and effectiveness of the medical products marketed to the American public.